Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma

Creaney, Jenette; Yeoman, Deborah; Demelker, Yvonne; Segal, Amanda; Musk, Arthur W.; Skates, Steven J.; Robinson, B. W.

doi:10.1097/jto.0b013e318180477b

Cited by 107 publications

(113 citation statements)

References 30 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…The same results were obtained in a 2012 Italian study, with mean SMRP levels of 0.51 nmol/L in benign disease and 0.43 nmol/L in healthy exposed population 62 . Similar findings were documented in numerous other studies 6,52,57,[63][64][65][66] . The presented study also showed statistically significantly higher mesothelin levels in a group of persons with just benign findings than in a group with no abnormalities detected by X-ray (0.755 ± 0.543 vs. 0.50 ± 0.35, P<0.001).…”

Section: Discussionsupporting

confidence: 79%

“…Another finding in many studies was statistically significantly higher mesothelin levels in mesothelioma than in metastatic involvement of the pleura but also statistically significantly higher mesothelin concentrations in metastatic pleural disease compared with asbestos-exposed individuals (healthy and/or with benign disease) (ref. 37,63,65,70 ). Large differences in results between individual studies are probably due to different cut-off values used.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Jakubec¹,

Pelclová²,

Smolková³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. Pleural mesothelioma is a highly aggressive and difficult-to-treat form of cancer induced by asbestos in 80-90% of cases. The population group most at risk of the condition are asbestos-exposed workers. Mesothelin or soluble mesothelin-related protein (SMRP) is studied as a potential marker of mesothelioma in the at-risk population. Methods. The study comprised 239 subjects with a mean duration of occupational exposure to asbestos of 19.9 years. In all of them, a complete medical history was taken, focused on exposure duration and a physical examination, a chest X-ray or other imaging investigations and a lung function test were performed. Their serum SMRP levels were measured and biopsy samples were taken to diagnose pleural disease. Based on the above examinations, the subjects were classified into subgroups and serum SMRP concentrations were statistically analyzed with respect to individual parameters. Results. In asbestos-exposed individuals, mesothelin levels were significantly higher in those with pathological X-ray findings than in those with normal X-ray results (0.78 ± 0.63 vs. 0.50 ± 0.35, P<0.0001). The group of patients with benign disease had statistically significantly higher mesothelin levels than those with normal X-ray findings (0.755 ± 0.543 vs. 0.50 ± 0.35, P<0.001). In the group with present malignant processes, mesothelin levels were higher than in individuals with benign disease (1.19 ± 0.89 vs. 0.76 ± 0.54, P=0.015). Only a weak correlation was found between mesothelin levels and asbestos exposure duration. There were relatively high sensitivity and high specificity (75% and 90.6%, respectively) of serum mesothelin for pleural mesothelioma. However, given the small number of mesothelioma cases in the group, the results cannot be considered as statistically significant. Conclusions. In persons followed up for asbestos exposure, increased mesothelin levels signalize pathological processes in the chest and correlate with severity of the disease. The study suggests that mesothelin cannot be considered a reliable marker for the early stage of malignant degeneration of pleural disease but only an additional criterion for examination of the followed-up individuals.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Jakubec¹,

Pelclová²,

Smolková³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…These first investigations as well as another short Japanese series [84] suggested higher diagnostic capabilities than soluble mesothelin. However these encouraging results were not confirmed by a larger series of patients [73]. Thus, today mesothelin remains the most interesting diagnostic marker despite its suboptimal sensitivity.…”

Section: The Megakaryocyte Potentiating Factormentioning

confidence: 59%

“…A few publications have tried to combine soluble mesothelin with other markers. To date no combination has been proved superior to soluble mesothelin alone either if combined with CA 125 [30], with hyaluronic acid or with MPF and/or osteopontin [73]. Some authors have suggested that the association of Cyfra 21.1 to soluble mesothelin may be useful [24] but the perceived utility may depend on how the data is analysed (i.e.…”

Section: Mesothelinmentioning

confidence: 99%

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Grigoriu

Grigoriu²,

Chahine

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Malignant mesothelioma has a very dismal prognosis with very few patients surviving one year after diagnosis. Early multimodal treatment, however, is expected to improve the outcome. Today, there is a strong need to have disease markers which could be used for screening, diagnosing, and/or monitoring tumour response to treatment. Old markers such as hyaluronic acid, various cytokeratin fragments (CYFRA 21.1, TPA) and other cancer antigens (CA 15.3, CA 125 or CA 19.9 or CEA) are not sensitive or specific enough and cannot be used in practice. More recently new molecules, such as soluble mesothelin and osteopontin, have been proposed for diagnostic purposes. Soluble mesothelin has a good specificity but has a suboptimal sensitivity being negative in all sarcomatoid and in up to one half of epithelioid mesothelioma. On the contrary osteopontin has an inadequate specificity. Combining different markers together does not lead to an improvement in diagnostic accuracy. Neither marker can be used for screening purposes, the main limitation being the very low incidence of the disease in the at-risk, asbestos exposed population. Mesothelin is also a promising marker for monitoring response to treatment but published data is still insufficient to make recommendations. There is still a strong need for research is this area both in order to discover new markers as well as to correct the positioning of each existing molecule (alone or in combination) is the evaluation of the patients with a mesothelioma.

show abstract

“…However, these are as yet imperfect [11][12][13][14]. One novel method of biomarker analysis is through exhaled breath profiling.…”

mentioning

confidence: 99%

A breath test for malignant mesothelioma using an electronic nose

et al. 2011

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is a rare tumour which is difficult to diagnose in its early stages. Earlier detection of MM could potentially improve survival. Exhaled breath sampling of volatile organic compounds (VOCs) using a carbon polymer array (CPA) electronic nose recognises specific breath profiles characteristic of different diseases, and can distinguish between patients with lung cancer and controls. With MM, the potential confounding effect of other asbestos-related diseases (ARDs) needs to be considered. We hypothesised that as CPA electronic nose would distinguish patients with MM, patients with benign ARDs, and controls with high sensitivity and specificity.20 MM, 18 ARD and 42 control subjects participated in a cross-sectional, case-control study. Breath samples were analysed using the Cyranose 320 (Smiths Detection, Pasadena, CA, USA), using canonical discriminant analysis and principal component reduction.10 MM subjects created the training set. Smell prints from 10 new MM patients were distinguished from control subjects with an accuracy of 95%. Patients with MM, ARDs and control subjects were correctly identified in 88% of cases.Exhaled breath VOC profiling can accurately distinguish between patients with MM, ARDs and controls using a CPA electronic nose. This could eventually translate into a screening tool for high-risk populations.

show abstract

Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma

Abstract: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.

Cited by 107 publications

References 30 publications

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Clinical utility of diagnostic markers for malignant pleural mesothelioma

A breath test for malignant mesothelioma using an electronic nose

Contact Info

Product

Resources

About